Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis

Clinical Pharmacology and Therapeutics
A Racine-PoonW Frank

Abstract

The efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, a recombinant monoclonal mouse-human chimeric anti-human immunoglobulin E (IgE) antibody were evaluated for 153 patients with seasonal allergic rhinitis treated with placebo or with 15, 30, or 60 mg CGP 51901 in six biweekly doses. Seasonal allergic rhinitis was chosen to validate the concept of anti-IgE therapy because the causal and temporal relation between allergen confrontation and IgE-mediated evocation of symptoms is firmly established. A sustained 85% or greater reduction of serum free IgE levels was shown to be effective in improving clinical symptoms. The concentration of CGP 51901 needed to maintain 85% or greater reduction of IgE was estimated to be about 5000 ng/ml. Baseline IgE levels and body weights of the patients greatly influenced the pharmacokinetic and pharmacodynamic profiles of CGP 51901. A population model was developed and refined to take into account patient baseline IgE level and body weight. The model was able to help predict multiple-dose pharmacokinetic and pharmacodynamic profiles on the basis of single-dose pharmacokinetic and pharmacodynamic measurements in the therapeutically effective dose range.

References

Jan 1, 1991·International Archives of Allergy and Applied Immunology·C H HeusserK Wagner
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Jun 24, 1986·Journal of Immunological Methods·D M Wojchowski, A J Sytkowski
Jul 1, 1995·American Journal of Respiratory Cell and Molecular Biology·A J CoyleG P Anderson
Jan 1, 1994·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·G G BrusselleH Bluethmann

❮ Previous
Next ❯

Citations

Sep 25, 2004·Journal of Pharmaceutical Sciences·Evelyn D LoboJoseph P Balthasar
Dec 16, 2010·Pharmaceutics·Rong Shi, Hartmut Derendorf
Jul 7, 2001·American Journal of Therapeutics·A M Fendrick, J L Baldwin
Feb 5, 2000·Nature Biotechnology·T W Chang
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·D Reichmuth, R F Lockey
Apr 23, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Molly VernerssonLars Hellman
Apr 7, 2020·Allergy·Pascal Guntern, Alexander Eggel
Apr 9, 1998·Statistical Methods in Medical Research·A Racine-Poon, J Wakefield
Apr 20, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Mitchell E ReffGary Braslawsky
Nov 15, 2001·The Journal of Allergy and Clinical Immunology·J BousquetUNKNOWN World Health Organization
Feb 7, 2001·Biochemical Pharmacology·W S Wong, D S Koh
Oct 2, 2001·Critical Reviews in Oncology/hematology·M E Reff, C Heard
Aug 6, 2004·Journal of Pharmaceutical Sciences·Lisa TangBernd Meibohm

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.